JP4660094B2 - 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物 - Google Patents

新生物を治療するためのＥｒｂＢ３に基づく方法および組成物 Download PDF

Info

Publication number
JP4660094B2
JP4660094B2 JP2003578561A JP2003578561A JP4660094B2 JP 4660094 B2 JP4660094 B2 JP 4660094B2 JP 2003578561 A JP2003578561 A JP 2003578561A JP 2003578561 A JP2003578561 A JP 2003578561A JP 4660094 B2 JP4660094 B2 JP 4660094B2
Authority
JP
Japan
Prior art keywords
protein
erbb
amino acid
acid sequence
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003578561A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005533488A (ja
Inventor
ミンドン チョウ
Original Assignee
ゼンサン （シャンハイ） サイ−テク． リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CNB02116259XA external-priority patent/CN1219882C/zh
Application filed by ゼンサン （シャンハイ） サイ−テク． リミテッド filed Critical ゼンサン （シャンハイ） サイ−テク． リミテッド
Publication of JP2005533488A publication Critical patent/JP2005533488A/ja
Application granted granted Critical
Publication of JP4660094B2 publication Critical patent/JP4660094B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2003578561A 2002-03-26 2003-03-26 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物 Expired - Fee Related JP4660094B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB02116259XA CN1219882C (zh) 2002-03-18 2002-03-26 以erbb－3为基础的用于肿瘤治疗的方法和组合物
PCT/CN2003/000217 WO2003080835A1 (en) 2002-03-26 2003-03-26 Erbb3 based methods and compositions for treating neoplasms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010101148A Division JP5249282B2 (ja) 2002-03-26 2010-04-26 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物

Publications (2)

Publication Number Publication Date
JP2005533488A JP2005533488A (ja) 2005-11-10
JP4660094B2 true JP4660094B2 (ja) 2011-03-30

Family

ID=28048642

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003578561A Expired - Fee Related JP4660094B2 (ja) 2002-03-26 2003-03-26 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物
JP2010101148A Expired - Lifetime JP5249282B2 (ja) 2002-03-26 2010-04-26 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010101148A Expired - Lifetime JP5249282B2 (ja) 2002-03-26 2010-04-26 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物

Country Status (7)

Country Link
US (2) US7919098B2 (cg-RX-API-DMAC7.html)
EP (2) EP2400021B1 (cg-RX-API-DMAC7.html)
JP (2) JP4660094B2 (cg-RX-API-DMAC7.html)
CN (1) CN100424175C (cg-RX-API-DMAC7.html)
AU (1) AU2003218600C1 (cg-RX-API-DMAC7.html)
CA (1) CA2480099C (cg-RX-API-DMAC7.html)
WO (1) WO2003080835A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
RU2473560C2 (ru) * 2005-11-02 2013-01-27 Дьюк Юниверсити Совместная химиотерапия и иммунотерапия
US20070190127A1 (en) 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
DK2129396T3 (da) 2007-02-16 2013-11-25 Merrimack Pharmaceuticals Inc Antistoffer mod ErbB3 og anvendelser deraf
US20090156488A1 (en) * 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
WO2009157919A1 (en) * 2008-06-23 2009-12-30 Tumor Biology Investment Group, Inc. SOLUBLE ErbB3 DETECTION, REGULATION AND TREATMENT OF CANCER
CA2732658A1 (en) * 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
WO2010060266A1 (en) * 2008-11-28 2010-06-03 Zensun (Shanghai) Science & Technology Limited Neuregulin and cardiac stem cells
PL2719708T3 (pl) 2009-11-13 2018-04-30 Daiichi Sankyo Europe Gmbh Materiał i sposoby leczenia lub zapobiegania chorobom związanym z HER-3
ES2571226T3 (es) 2009-12-22 2016-05-24 Roche Glycart Ag Anticuerpos anti-HER3 y usos de los mismos
NZ602084A (en) 2010-03-11 2014-07-25 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
IT1402149B1 (it) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2.
ITRM20100577A1 (it) 2010-11-02 2012-05-03 Takis Srl Immunoterapia contro il recettore erbb-3
TWI418362B (zh) * 2010-11-19 2013-12-11 Univ Nat Pingtung Sci & Tech 溶血性巴斯德桿菌重組外膜脂蛋白e及含此之疫苗組成物
US20140134170A1 (en) 2011-03-11 2014-05-15 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
JP2014509593A (ja) 2011-03-15 2014-04-21 メリマック ファーマシューティカルズ インコーポレーティッド ＥｒｂＢ経路阻害剤に対する耐性の克服
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
BR112014012539B1 (pt) 2011-11-23 2022-12-20 Medimmune, Llc Anticorpo que se liga especificamente a her3, composição compreendendo o mesmo, e usos do anticorpo
US9956276B2 (en) * 2012-01-19 2018-05-01 Duke University Vaccines against antigens involved in therapy resistance and methods of using same
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
WO2016007499A1 (en) 2014-07-07 2016-01-14 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same
US20170196952A1 (en) 2014-07-07 2017-07-13 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
JP2017528430A (ja) * 2014-07-17 2017-09-28 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 免疫に基づく療法のための、免疫原性ｍｈｃクラスｉｉペプチドの同定
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CA2992925A1 (en) * 2015-07-17 2017-01-26 The Trustees Of The University Of Pennsylvania Identification of immunogenic mhc class ii peptides for immune-based therapy
JP7014710B2 (ja) * 2015-09-02 2022-02-01 ザ クリーブランド クリニック ファウンデーション 卵巣癌ワクチン
US11253580B2 (en) 2016-01-07 2022-02-22 Duke University Cancer vaccines and methods of delivery
US11008402B2 (en) * 2016-09-15 2021-05-18 Universitat Stuttgart Antigen binding protein against HER3
US11224665B2 (en) 2016-10-05 2022-01-18 Duke University Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same
US10487143B2 (en) 2016-10-05 2019-11-26 Duke University Vaccines against HER3 antigens and methods of using the same
CA3076012A1 (en) * 2017-09-27 2019-04-04 L2 Diagnostics, Llc Erbb peptide pharmaceutical and vaccine compositions and therapeutics uses thereof for cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
DE69033842T2 (de) 1989-08-04 2002-06-20 Schering Ag Äusserliche domäne von c-erbb-2:gp75
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5578482A (en) 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
DE4221256C2 (de) 1992-06-26 1997-07-10 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US5741511A (en) 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
US5941868A (en) 1995-12-22 1999-08-24 Localmed, Inc. Localized intravascular delivery of growth factors for promotion of angiogenesis
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
NZ331360A (en) 1996-03-27 2000-03-27 Genentech Inc an antibody which binds to a ErbB3 protein and reduces heregulin-induced formation of a ErbB2-ErbB3 protein complex
EP0912734B1 (en) * 1996-07-12 2010-11-03 Genentech, Inc. Chimeric heteromultimer adhesins
KR100628846B1 (ko) 1996-10-18 2006-09-29 제넨테크, 인크. 항-ＥｒｂＢ２ 항체
US5981201A (en) 1997-01-08 1999-11-09 Beth Israel Deaconess Medical Center Methods of detection and treatment of breast cancer
JP4515542B2 (ja) 1997-02-10 2010-08-04 ジェネンテック， インコーポレイテッド ヒレグリン変異体
SE9703226D0 (sv) 1997-09-08 1997-09-08 Astra Ab New pharmaceutical composition
US6197801B1 (en) 1998-01-14 2001-03-06 Usa Doctors Products, Inc. Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction
US5962274A (en) 1998-03-13 1999-10-05 Wake Forest University Viral vector directed to predetermined target cells
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
CA2377665A1 (en) 1999-07-06 2001-01-11 General Atomics Methods and compositions for assaying analytes
EP1282440A1 (en) 2000-05-15 2003-02-12 Pharmacia Italia S.p.A. Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumor agents
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
WO2006091209A2 (en) 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
DK2129396T3 (da) 2007-02-16 2013-11-25 Merrimack Pharmaceuticals Inc Antistoffer mod ErbB3 og anvendelser deraf

Also Published As

Publication number Publication date
CA2480099C (en) 2019-01-08
US7919098B2 (en) 2011-04-05
CN100424175C (zh) 2008-10-08
US20110229478A1 (en) 2011-09-22
WO2003080835A1 (en) 2003-10-02
EP1495123A1 (en) 2005-01-12
AU2003218600C1 (en) 2009-12-17
US20080057064A1 (en) 2008-03-06
EP2400021B1 (en) 2016-11-30
EP2400021A3 (en) 2012-03-21
AU2003218600B2 (en) 2009-05-21
CA2480099A1 (en) 2003-10-02
JP2010213710A (ja) 2010-09-30
JP2005533488A (ja) 2005-11-10
EP1495123B1 (en) 2013-10-30
JP5249282B2 (ja) 2013-07-31
AU2003218600A1 (en) 2003-10-08
EP1495123A4 (en) 2009-06-24
CN1650011A (zh) 2005-08-03
EP2400021A2 (en) 2011-12-28

Similar Documents

Publication Publication Date Title
JP5249282B2 (ja) 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物
US10842855B2 (en) Vaccines against an oncogenic isoform of ESR1 and methods of using the same
US11235043B2 (en) Vaccines against antigens involved in therapy resistance and methods of using same
JP2007297398A (ja) 突然変異上皮成長因子受容体を標的とする試薬および方法
JP2003524021A (ja) 悪性中皮腫の診断および治療のための組成物および方法
JP2021525283A (ja) ＣＤ３００ｃの発現抑制剤または活性抑制剤を含む癌の予防または治療用薬学的組成物
Aurisicchio et al. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9
JPWO2005071075A1 (ja) 上皮細胞増殖因子受容体（ｅｇｆｒ）由来ペプチド
US8748170B2 (en) Polypeptides derived from cyclin B1 and uses thereof
JP2010508020A (ja) Ｌｉｇｈｔを介する抗細胞増殖性組成物および方法
WO2022100585A1 (zh) 抗Her-2抗体-趋化因子融合蛋白及其制法和应用
AU766898B2 (en) Tumor associated antigen 791Tgp72
KR20090099011A (ko) 암의 치료를 위한 수술, 화학요법 또는 방사선요법과 조합된 면역요법에서 ｍａｇｅ ａ３－단백질 ｄ 융합 항원의 용도
US20080095789A1 (en) Vaccine
CA3195594A1 (en) Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
KR102829639B1 (ko) c-Met의 에피토프를 포함하는 암 백신 및 이의 용도
JP2025509401A (ja) 頭頸部がん治療のための三重複合薬物投与療法
WO2025101877A1 (en) Platform for increasing hla class i antigen presentation utilizing engineered chaperone fusion proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20051227

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20051227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20051228

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20051228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20051227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090828

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100426

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100928

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101130

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101228

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140107

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4660094

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees